Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm, Single Stage Phase II Trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer

Next Previous
Trial Profile

A Single Arm, Single Stage Phase II Trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trametinib (Primary) ; Uprosertib (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 May 2019 Results to evaluate the inhibition of PI3K and RAS signaling by combining the MEK inhibitor trametinib and the AKT inhibitor GSK2141795 in recurrent cervical cancer are published in the Gynecologic Oncology.
    • 16 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
    • 05 Apr 2017 Results analysing clinical activity and safety of trametinib [GSK-1120212] + GSK2141795 in patients with recurrent or metastatic cervical cancer, presented at the 108th Annual Meeting of the American Association for Cancer Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top